Ambit left to mull options as quizartinib partner Astellas pulls out of alliance
This article was originally published in Scrip
Executive Summary
Ambit Biosciences has been left holding its most advanced drug candidate alone - at least for now - after Astellas exercised its right to end a 2009 global license agreement with the private US firm for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, led by quizartinib.